Logo

American Heart Association

  111
  0


Final ID: Sa3104

Inactive Matrix Gla Protein and Cardiovascular Outcomes: the Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Background: Matrix Gla protein (MGP) inhibits arterial calcification. Higher inactive MGP, dephosphorylated-uncarboxylated (dp-ucMGP), is positively associated with vascular calcification, possibly portending cardiovascular events. The objective was to determine the association of dp-ucMGP with incident cardiovascular disease (CVD) events and mortality in the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: MESA is a cohort study of 45-84 year-old individuals enrolled between 2000-02 with adjudicated outcomes through 2019. Dp-ucMGP was measured at baseline in n=2663 participants with cardiac computed tomography at Exams 1 (2000-02) and 5 (2010-12). Using age-stratified Cox proportional hazard models, adjusted for sex, race-ethnicity, body mass index, systolic blood pressure, statin use, anti-hypertensive medication use, smoking status, physical activity, alcohol use, diabetes, high density lipoprotein, low density lipoprotein, triglycerides, phosphate, and estimated glomerular filtration rate, we determined the association of dp-ucMGP with risk of all CVD (mean follow-up 16 + 4 years), hard CVD (17 + 3 years), hard CHD (17 + 3 years), and all-cause mortality (18 + 2 years).
Results: The youngest age quartile (45-53-years-old) with higher dp-ucMGP levels (520-2934 pmol/L) had an increased risk of all CVD (HR 3.01 [95% CI 1.56, 5.80], p=0.001), hard CVD (HR 2.78 [95% CI 1.29, 6.02], p=0.009), hard CHD (HR 3.37 [95% CI 1.29, 8.81], p=0.013) and all-cause mortality (HR 2.69 [95% CI 1.06, 6.79], p=0.037) compared to dp-ucMGP levels between 150-519 pmol/L in maximally adjusted models. There was no relationship with any outcomes for the other age quartiles (Table).
Conclusions: Middle aged individuals with elevated dp-ucMGP levels (>520 pmol/L) had an increased risk of incident CVD, CHD, and all-cause mortality.
  • Berlot, Ashley  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Bortnick, Anna  ( WEILER HOSP , Bronx , New York , United States )
  • Fu, Xueyan  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Shea, Kyla  ( TUFTS UNIVERSITY , Boston , Massachusetts , United States )
  • Tracy, Russell  ( UNIVERSITY VERMONT , Colchester , Vermont , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Kim, Ryung  ( Albert Einstein College of Medicine , Bronx , New York , United States )
  • Naveed, Mahim  ( San Francisco VA , San Francisco , California , United States )
  • Booth, Sarah  ( Tufts University , Boston , Massachusetts , United States )
  • Kizer, Jorge  ( San Francisco VA , San Francisco , California , United States )
  • Author Disclosures:
    Ashley Berlot: DO NOT have relevant financial relationships | Anna Bortnick: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Getinge, Honoraria to Institution:Past (completed) ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Research Funding (PI or named investigator):CSL Behring:Past (completed) ; Other (please indicate in the box next to the company name):Zoll, Honoraria to Institution:Past (completed) | Xueyan Fu: DO NOT have relevant financial relationships | Kyla Shea: DO NOT have relevant financial relationships | Russell Tracy: No Answer | Matthew Budoff: DO have relevant financial relationships ; Researcher:General Electric:Active (exists now) | Ryung Kim: No Answer | Mahim Naveed: DO NOT have relevant financial relationships | Sarah Booth: No Answer | JORGE KIZER: DO have relevant financial relationships ; Individual Stocks/Stock Options:Abbott:Past (completed) ; Individual Stocks/Stock Options:Pfizer:Past (completed) ; Individual Stocks/Stock Options:Merck:Past (completed) ; Individual Stocks/Stock Options:Medtronic:Past (completed) ; Individual Stocks/Stock Options:Lilly:Past (completed) ; Individual Stocks/Stock Options:Johnson & Johnson:Past (completed) ; Individual Stocks/Stock Options:Bristol Myers Squibb:Past (completed) ; Individual Stocks/Stock Options:AbbVie:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Clinical Prediction, Prognosis, and Decision-Making

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
A Scoping Review Exploring Cardiovascular Risk and Health Metrics and Cancer Prediction

Kim Ji-eun, Henriquez Santos Gretell, Kumar Sant, Livinski Alicia, Vo Jacqueline, Joo Jungnam, Shearer Joe, Hashemian Maryam, Roger Veronique

A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program

Djousse Luc, Leesch Tharen, Pena David, Gaziano Michael, Ward Rachel, Wellman Helen, Yel Nedim, Santos Abigail, Delgrande Jen, Fink Abigail, Colson Kristin, Pan Eddie

More abstracts from these authors:
Polygenic Risk Scores Do Not Fully Explain Resilience to CVD in Individuals from Long Lived Families: UK Biobank

Ye Kenny, Charla Joseph, Kankaria Rohan, Zhang Zhendong, Kizer Jorge, Rodriguez Carlos, Milman Sofiya, Barzilai Nir, Bortnick Anna

Relations Of Inflammatory Biomarkers With Incident Clinical Peripheral Artery Disease In Older Adults

Dosanjh Jagjot, Kizer Jorge, Shitole Sanyog, Garg Parveen, Mukamal Kenneth, Cushman Mary, Sitlani Colleen, Walston Jeremy, Reiner Alex, Tracy Russell, Psaty Bruce

You have to be authorized to contact abstract author. Please, Login
Not Available